AMRX Stock: Price, Earnings History and SEC Filings
Amneal Pharmaceuticals, Inc. (AMRX) last traded at $21.51, up 0.75% on the latest session and up 6.8% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.27 against an analyst estimate of $0.24, a beat of 12.5%.
$21.51 +0.75%
1 month+6.80%
52-week high$21.68
52-week low$10.68
Volume2.77M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AMRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $0.27 | $0.24 | +12.50% |
| Mar 2026 | Apr 22, 2026 | $0.26 | $0.15 | +73.33% |
| Dec 2025 | Feb 27, 2026 | $0.19 | $0.17 | +11.76% |
| Sep 2025 | Oct 30, 2025 | $0.15 | $0.12 | +25.00% |
AMRX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for AMRX
SEC filing data is not available right now. You can search for AMRX on SEC EDGAR.
AMRX news
- GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthOct 30, 2026 · finance.yahoo.com
- INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceOct 30, 2026 · finance.yahoo.com
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 30, 2026 · finance.yahoo.com
- VKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesOct 29, 2026 · finance.yahoo.com
- Amarin's Q3 Earnings Beat Estimates, Revenues Miss MarkOct 29, 2026 · finance.yahoo.com
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesOct 29, 2026 · finance.yahoo.com
- Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Where Does Amneal Pharmaceuticals (AMRX) Value Sit After A 4.4x Run?Oct 29, 2026 · finance.yahoo.com
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. (AMRX) is a US-listed public company on Nasdaq.